Clinical Trials Logo

Clinical Trial Summary

Background:

Clopidogrel, an antiplatelet prodrug, is widely used for prevention of the recurrent cardiovascular events. CYP2C19 is one of the crucial enzymes for the activation of clopidogrel. Recent studies, mostly done in cardiovascular patients, showed association of the CYP2C19 genotypes with recurrent cardiovascular events. However, prospective data on the impact of the genetic variants in stroke patients are limited.

Methods:

Five hundred and eighteen Japanese non-acute stroke patients treated with clopidogrel were registered at 14 institutions. Three CYP2C19 variants (CYP2C19*2, *3, *17) were genotyped and the patients were classified into three clopidogrel metabolizer groups inferred from the CYP2C19 genotypes: extensive (EM: *1/*1), intermediate (IM: *1/*2 or *1/*3), and poor (PM: *2/*2, *2/*3, or *3/*3). The CYP2C19*17 carriers were excluded from the analysis. The antiplatelet effects of clopidogrel were assessed by Adenosine diphosphate (ADP) -induced platelet aggregation and vasodilator-stimulated phosphoprotein (VASP) phosphorylation, expressed as VASP index. The endpoint was the composite incidence of stroke, transient ischemic attack, myocardial infarction, revascularization, other thromboembolic disease, or cardiovascular death during 2 years of follow-up.


Clinical Trial Description

n/a


Study Design

Observational Model: Cohort, Time Perspective: Prospective


Related Conditions & MeSH terms


NCT number NCT02711410
Study type Observational
Source National Cerebral and Cardiovascular Center
Contact
Status Completed
Phase N/A
Start date October 2009
Completion date October 2015

See also
  Status Clinical Trial Phase
Completed NCT02554006 - Predischarge Bundle to Minimize Negative Impact on Quality of Life of Nuisance Bleedings N/A
Recruiting NCT04796714 - AntiPlatelet theraPy stratEgy followiNg Left Atrial appenDAGe closurE Phase 4
Completed NCT05278637 - GM03 - Platelet RNA Signatures of Aspirin Early Phase 1
Recruiting NCT03288441 - Management and Outcomes of Anti-thrombotic Medication Use in Thrombocytopenia
Recruiting NCT05306951 - Correct Timing of Head Imaging in Trauma
Recruiting NCT05732701 - Algorithm-based Tailoring of Dual Antiplatelet Therapy to Improve Outcomes Following Percutaneous Coronary Interventions N/A
Recruiting NCT05702463 - Assessing Pharmacokinetics and Pharmacodynamics of Daily Enteric-coated Aspirin in Patients With StablE Diabetes II Phase 1
Not yet recruiting NCT03862651 - Maintenance Of aNtiplatElet Therapy in Patients With Coronary Stenting Undergoing Surgery (MONET BRIDGE) Phase 2
Completed NCT01354808 - ACCEL-LOADING-ACS Study Phase 4
Completed NCT00799396 - Determining Genetic Role in Treatment Response to Anti-Platelet Interventions (The PAPI Study) Phase 4
Completed NCT00325390 - Efficacy and Safety in Patients With Acute Coronary Syndrome Without ST-Segment Elevation Phase 3
Completed NCT04999293 - Ticagrelor in Elderly Patients Undergoing Percutaneous Coronary Intervention
Completed NCT04328883 - Pharmacodynamics and Pharmacokinetics of Aspirin Inhalation Powder With Non-Enteric-Coated Chewable Aspirin Phase 1
Completed NCT02808767 - Comparison of Prasugrel and Ticagrelor in the Treatment of Acute Myocardial Infarction Phase 4
Completed NCT00769938 - WOEST ( What is the Optimal antiplatElet & Anticoagulant Therapy in Patients With Oral Anticoagulation and Coronary StenTing) Phase 4
Completed NCT03599284 - The Efficacy, Safety and Pharmacokinetic of Antiplatelet Therapy for Vicagrel Phase 2
Completed NCT03785509 - The Compliance of DAPT and Statins on Clinical Outcomes in Percutaneous Coronary Intervention Patients
Unknown status NCT01103843 - Plavix, Prasugrel and Drug Eluting Stents Pilot Trial N/A
Active, not recruiting NCT03462498 - ShorT and OPtimal Duration of Dual AntiPlatelet Therapy-2 Study for the Patients With ACS Phase 4